Pear-006

Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pharmaceutical Business Review
Wed, 12/18/19 - 10:31 am
Pear Therapeutics
MS
multiple sclerosis
Pear-006
clinical trials